Novartis Institutes for Biomedical Research
8
43M
6
1
0.25
4
- Areas of investment
Summary
The fund is constantly included in 2-6 deals per year. The high activity for fund was in 2019. Deals in the range of 10 - 50 millions dollars are the general things for fund.
Moreover, a startup needs to be at the age of 4-5 years to get the investment from the fund. Among the various public portfolio startups of the fund, we may underline TScan Therapeutics, Cadent Therapeutics, Vor Biopharma The fund has specific favorite in a number of founders of portfolio startups. Among the most popular fund investment industries, there are Health Care, Pharmaceutical.
The typical case for the fund is to invest in rounds with 5-6 participants. Despite the Novartis Institutes for Biomedical Research, startups are often financed by Slater Technology Fund, Clal Biotechnology Industries, Atlas Venture. The meaningful sponsors for the fund in investment in the same round are Novartis Venture Fund, Longwood Founders Fund, GV.
Investments analytics
Analytics
- Total investments
- 8
- Lead investments
- 1
- Exits
- 4
- Follow on index
- 0.25
- Investments by industry
- Biotechnology (8)
- Health Care (7)
- Therapeutics (6)
- Pharmaceutical (5)
- Medical Device (2) Show 5 more
- Investments by region
-
- United States (8)
- Peak activity year
- 2020
- Number of Unicorns
- 1
- Number of Decacorns
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 7
- Avg. valuation at time of investment
- 345M
- Group Appearance index
- 1.00
- Avg. company exit year
- 10
- Avg. multiplicator
- 11.55
- Strategy success index
- 0.90
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| TScan Therapeutics | 10 Jan 2020 | Biotechnology, Health Care, Pharmaceutical, Therapeutics | Early Stage Venture | 35M | United States, Massachusetts |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.